
|Articles|October 31, 2012
SARcode reports phase III results for lifitegrast
SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: A new biomechanical paradigm for presbyopia
2
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
3
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined
4
Managing Unique Dry Eye Disease Subtypes in Patients
5

















































.png)


